Table 6.
Impact of the number of administrated doses.
| Outcome | 3 Doses (95% CI) |
2 Doses (95% CI) |
1 Dose (95% CI) |
|---|---|---|---|
| Incident of HPV 16/18 infection [53] | 4.3% (3.5% to 5.3%) |
0, 6 months; 3.8% (1.0% to 10.1%) 0, 1 month; 3.6% (1.6% to 7.1%) |
3.6% (0.3% to 4.9%) |
| Vaccine efficacy against prevalence of HPV 16/18 [76] | 80.2% (70.7% to 87.0%) |
83.8% (19.5% to 99.2%) |
82.1% (40.2% to 97.0%) |
| Relative risk of 6 months persistent HPV 16/18 infection in women (naive HPV infection) [15] | 0.067 (0.049 to 0.093) |
0.126 (0.126 to 0.544) |
0.045 (0.003 to 0.774) |
| Incidence rate ratios for cervical intraepithelial neoplasia grade 2 compared with unvaccinated women [77] | 0.43 (0.36 to 0.51) |
0.49 (0.32 to 0.76) |
0.34 (0.13 to 0.87) |
| Incidence rate ratios for cervical intraepithelial neoplasia grade 3 compared with unvaccinated women [77] | 0.37 (0.30 to 0.45) |
0.38 (0.22 to 0.66) |
0.38 (0.14 to 0.98) |
| Incidence rate ratios for cervical intraepithelial neoplasia grade 2; comparison of the number of doses administered among vaccinated women [77] | 0.99 | 1.00 | 1 |
| (0.64 to 1.53) | (0.61 to 1.64) | ||
| Incidence rate ratios for cervical intraepithelial neoplasia grade 3; comparison of the number of doses administered among vaccinated women [77] | 0.95 | 0.89 | 1 |
| (0.60 to 1.51) | (0.53 to 1.52) |